Adimab
6 known investors
Adimab operates a yeast-based antibody discovery and engineering platform that produces fully human antibodies, heavy-chain antibodies, and multispecifics (including T-cell engagers) for biopharma partners. It offers services from antigen acquisition through preclinical lead generation, including AI-guided protein engineering, and works with partners through discovery, platform licensing, and technology-module collaboration models.
Founder mafia
4 people who came through Adimab went on to found or lead other companies.
Investors · 6
Frequently asked questions
- What does Adimab do?
- Adimab operates a yeast-based antibody discovery and engineering platform that produces fully human antibodies, heavy-chain antibodies, and multispecifics (including T-cell engagers) for biopharma partners. It offers services from antigen acquisition through preclinical lead generation, including AI-guided protein engineering, and works with partners through discovery, platform licensing, and technology-module collaboration models.
- Who are Adimab's investors?
- Adimab's investors include GrandBanks Capital, LaunchCapital, Lux Capital, Premji Invest, SV Health Investors, Mithril Capital Management.